Moderna's stock just doubled on cancer vaccine trial results. The mRNA platform they built for COVID is now showing real efficacy against melanoma when combined with checkpoint inhibitors. Phase 3 data dropped showing 49% reduction in recurrence/death risk vs standard care alone.
Technically interesting because they're using personalized neoantigen targeting - sequencing each patient's tumor, identifying mutations, then generating custom mRNA vaccines against those specific cancer proteins. Same lipid nanoparticle delivery system as their COVID shots.
This validates the broader thesis that mRNA isn't just for infectious disease. You can theoretically program it to train immune systems against any protein target. Cancer cells express mutated proteins that normal cells don't, making them ideal targets.
Market's pricing in the platform value now, not just one drug. If this approach works for melanoma, the same tech stack applies to other solid tumors. That's why you're seeing the 2x move - investors are revaluing the entire pipeline potential.
Technically interesting because they're using personalized neoantigen targeting - sequencing each patient's tumor, identifying mutations, then generating custom mRNA vaccines against those specific cancer proteins. Same lipid nanoparticle delivery system as their COVID shots.
This validates the broader thesis that mRNA isn't just for infectious disease. You can theoretically program it to train immune systems against any protein target. Cancer cells express mutated proteins that normal cells don't, making them ideal targets.
Market's pricing in the platform value now, not just one drug. If this approach works for melanoma, the same tech stack applies to other solid tumors. That's why you're seeing the 2x move - investors are revaluing the entire pipeline potential.
